Search Within

Prioty Islam

Formats
  1. Meeting Abstract (6)
  2. Research Letter (2)
  3. Review (1)
Groups
  1. Department of Medicine (8)
  2. Hematologic Malignancies, Division of (8)
  3. GME, Medicine (6)
  4. Graduate Medical Education (6)
  5. Hematology-Oncology Fellows (6)
  6. Adult Leukemia (4)

More Groups

People
  1. Lindsey Roeker (7)
  2. Meghan Thompson (6)
  3. Andrew Zelenetz (3)
  4. Anita Kumar (3)
  5. Gilles Salles (3)
  6. Jennifer Lue (3)

More People

Years
  1. 2025 (2)
  2. 2024 (4)
  3. 2023 (3)
Publications
  1. Blood (6)
  2. American Journal of Hematology (1)
  3. Blood Cancer Journal (1)
  4. Current Treatment Options in Oncology (1)
Publishers
  1. American Society of Hematology (6)
  2. John Wiley & Sons (1)
  3. Nature Publishing Group (1)
  4. Springer (1)

Results (9)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Prognostic implication of karyotypic evaluation in patients with Richter transformation in the modern era
    Research Letter

    Miller, C. R.; Huang, Y.; Allan, J. N.; Bhat, S. A.; Bond, D.; Brander, D.; Byrd, J. C.; Chavez, J.; Chong, E.; Danilov, A.; more...
    American Journal of Hematology (2025)

    Fulltext@MSK | Save
  • Outcomes of patients with Richter transformation who received no prior chemoimmunotherapy for their CLL
    Research Letter

    Kittai, A. S.; Huang, Y.; Miller, S.; Allan, J. N.; Bhat, S. A.; Bond, D. A.; Brander, D. M.; Byrd, J. C.; Chavez, J. C.; Chong, E.; more...
    Blood Cancer Journal (2025)

    Fulltext@MSK | Save
  • A multi-center retrospective study on complex karyotype in patients with Richter transformation who received no chemoimmunotherapy for their CLL
    Meeting Abstract

    Miller, C.; Huang, Y.; Allan, J. N.; Bhat, S. A.; Bond, D. A.; Brander, D. M.; Byrd, J. C.; Chavez, J. C.; Chong, E. A.; Danilov, A.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Multicenter phase II trial of zanubrutinib, obinutuzumab, and venetoclax (BOVen) in treatment-naive chronic lymphocytic leukemia: 5-Year follow up, retreatment outcomes, and Impact of MRD kinetics (ΔMRD400)
    Meeting Abstract

    Soumerai, J. D.; Dogan, A.; Seshan, V.; Flaherty, K. L.; Slupe, N.; Carter, J.; Hochberg, E.; Barnes, J. A.; Abramson, J. S.; Hamilton, A.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Minimal residual disease (MRD)-adapted duration of front-line venetoclax and obinutuzumab treatment for fit patients with chronic lymphocytic leukemia (CLL)
    Meeting Abstract

    Roeker, L.; Mato, A. R.; Zelenetz, A. D.; Park, J. H.; Geyer, M. B.; Derkach, A.; Nemirovsky, D.; Islam, P.; Falchi, L.; Palomba, M. L.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • A phase 1b study of DISC-0974, an anti-hemojuvelin antibody, in patients with myelofibrosis and anemia
    Meeting Abstract

    Gangat, N.; Foran, J. M.; Halpern, A. B.; Rampal, R.; Bose, P.; Hexner, E. O.; Talpaz, M.; Michaelis, L. C.; Islam, P.; Swords, R. T.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • A phase 2 study of minimal residual disease (MRD)-adapted front line venetoclax and obinutuzumab in fit patients with chronic lymphocytic leukemia (CLL): Effect of obinutuzumab on tumor lysis syndrome (TLS) risk and safety of outpatient venetoclax dose escalation
    Meeting Abstract

    Roeker, L. E.; Zelenetz, A. D.; Park, J. H.; Derkach, A.; Geyer, M. B.; Islam, P.; Falchi, L.; Palomba, M. L.; Kumar, A.; Salles, G.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Outcomes of patients with richter transformation without prior chemoimmunotherapy for CLL/SLL: An international multicenter retrospective study
    Meeting Abstract

    Kittai, A. S.; Huang, Y.; Miller, S.; Allan, J. N.; Bhat, S. A.; Bond, D. A.; Brander, D. M.; Byrd, J. C.; Chavez, J. C.; Chong, E. A.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Current treatment options in relapsed and refractory chronic lymphocytic leukemia/small lymphocytic lymphoma: A review
    Review

    Islam, P.
    Current Treatment Options in Oncology (2023)

    Fulltext@MSK | Save